UK Markets closed
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • FTSE 250

    19,123.71
    +430.71 (+2.30%)
     
  • AIM

    896.27
    +10.41 (+1.18%)
     
  • GBP/EUR

    1.1623
    -0.0023 (-0.20%)
     
  • GBP/USD

    1.2269
    +0.0008 (+0.0675%)
     
  • BTC-GBP

    17,424.72
    -132.52 (-0.75%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • DOW

    31,500.68
    +823.28 (+2.68%)
     
  • CRUDE OIL

    107.06
    -0.56 (-0.52%)
     
  • GOLD FUTURES

    1,828.10
    -2.20 (-0.12%)
     
  • NIKKEI 225

    26,491.97
    +320.77 (+1.23%)
     
  • HANG SENG

    21,719.06
    +445.16 (+2.09%)
     
  • DAX

    13,118.13
    +205.53 (+1.59%)
     
  • CAC 40

    6,073.35
    +190.02 (+3.23%)
     

Novartis buys UK's Gyroscope for $1.5 billion to get gene therapy for eye disease

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) - Swiss drugmaker Novartis AG is buying Gyroscope Therapeutics for up to $1.5 billion, looking to bolster its gene therapy roster with the British firm's treatment for geographic atrophy, a leading cause of blindness.

Gyroscope's parent company, London-listed healthcare investment firm Syncona Ltd, said on Wednesday that Novartis will pay $800 million upfront and up to $700 million in additional milestone payments.

Gyroscope's treatment for geographic atrophy, a disease of the retina that leads to blindness and for which there is currently no treatment, is in the second phase of clinical development.

Gene therapies are currently among the world's most expensive drugs. They aim to cure diseases by replacing the missing or defective version of a gene in a patient's cells with an intact gene.

Syncona will also receive low single-digit royalty from future sales of Gyroscope's gene therapy, and cash proceeds of 334 million pounds ($442.9 million) for its stake in the unit.

The deal, which Novartis plans to fund with cash in hand, comes after the Swiss drugmaker raised $20.7 billion by selling a nearly one-third voting stake in Roche last month.

($1 = 0.7542 pounds)

(Reporting by Sinchita Mitra and Pushkala Aripaka in Bengaluru, and Michael Shields in Zurich and Patricia Weiss in Frankfurt; Editing by Shounak Dasgupta and Devika Syamnath)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting